Pfizer earns positive Phase 3 in multiple myeloma; ICON overstated revenuenews2026-04-29T15:28:51+00:00April 29th, 2026|Endpoints News|
After Apellis deal, Biogen looks to fill early-stage pipelinenews2026-04-29T15:15:09+00:00April 29th, 2026|Endpoints News|
AstraZeneca rekindles UK relationship, pledges £300M to expandnews2026-04-29T15:03:28+00:00April 29th, 2026|Endpoints News|
Chiesi signs $1.9B deal to acquire KalVista and its approved drugnews2026-04-29T13:25:38+00:00April 29th, 2026|Endpoints News|
Should pharma be swinging bigger with AI? One top researcher wants to trynews2026-04-29T12:57:45+00:00April 29th, 2026|Endpoints News|
GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readoutsnews2026-04-29T11:22:30+00:00April 29th, 2026|Endpoints News|
MPM has collected three China drugs for its ‘best of both worlds’ strategynews2026-04-29T11:00:19+00:00April 29th, 2026|Endpoints News|
AstraZeneca cuts a couple of late-stage life-cycle trials after disappointing efficacynews2026-04-29T10:50:57+00:00April 29th, 2026|Endpoints News|
FDA debuts plan to collect real-time clinical trial datanews2026-04-28T18:19:33+00:00April 28th, 2026|Endpoints News|
The crown for healthcare admin tech is still up for grabsnews2026-04-28T17:36:38+00:00April 28th, 2026|Endpoints News|
